医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Macrogen Enters Exome Sequencing Analysis Service Provision Agreement with University College London

2015年05月18日 PM06:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

The personalized medicine and biotechnology company, Macrogen (CEO Hyonyong Chong, www.macrogen.com) (KOSDAQ:038290) has announced that the company has entered into a genome analysis service provision agreement with University College London (UCL, www.ucl.ac.uk) continuing from last year.

To enter this year’s provision agreement, Macrogen competed against multiple genome analysis service providers according to the designated competition agreement process hosted by UCL. By achieving outstanding assessments in data analysis, service quality, and reliability, Macrogen was selected as the final service provider for the second year in a row.

Through this agreement, Macrogen will provide exome sequencing service for neurodegenerative disease samples to the UCL Institute of Neurology. UCL is currently operating a project to identify genetic causation and risk factors for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative diseases by collecting samples from collaborating institutions in the United States and across Europe.

Macrogen offers the latest genome analysis equipment, including HiSeq X Ten from Illumina, the PacBio RS II from Pacific Biosciences, which enables the company to provide genome analysis service worldwide. The company is expanding its services to genome-based medical research and clinical diagnosis for patients.

In addition, Macrogen is holding a promotion package in celebration of the CI renewal for transcriptome sequencing and exome sequencing by offering one additional sample analysis for every six sample analyses. Also, a comprehensive service that doubles the efficiency of cohort-based mass genome analysis and exome analysis is provided through simultaneous execution of HiSeq X-based 15X human genome sequencing (HWGS, Whole Genome Sequencing) and HiSeq 2500-based 100X human exome sequencing (HWES, Human Whole Exome Sequencing).

Macrogen had previously entered a genome analysis service agreement with UCL’s Centre for Molecular Medicine through a designated competition agreement process last year, and has provided human exome sequencing service for inflammatory bowel disease samples for an in-house research project in the UCL Centre for Molecular Medicine.

Dr. Jose Miguel Bras of the UCL Institute of Neurology noted, “The service and analysis capabilities shown by Macrogen through the genome analysis service for the UCL Centre for Molecular Medicine last year were impressive.” He added, “I am expecting great things from the close relationship with Macrogen, as we partner in the neurodegenerative disease research project our Institute is currently undertaking.”

Hyonyong Chong, the CEO of Macrogen, said, “We’re very pleased to be selected, once again, as the research partner after passing the strict criteria of UCL despite intense competition. We will provide the best genome analysis service through close cooperation with UCL so that the project can successfully be completed. At the same time, we will expand the areas of cooperation based on our X-Genome service in the future.”

About University College London

UCL is London’s leading multidisciplinary university, with over 9,700 staff and 24,000 students. Over 140 nationalities are represented among UCL students with overseas students making up nearly a third of the student body. Based in the heart of Bloomsbury, UCL was the first university in England to welcome students of any class, race or religion, and the first to welcome women on equal terms with men. UCL’s excellence extends across all academic disciplines; from one of Europe’s largest and most productive centres for biomedical science interacting with eleven leading London hospitals, to world-renowned centres for architecture (UCL Bartlett) and fine art (UCL Slade School).
Find out more at http://www.ucl.ac.uk

About the Centre for Molecular Medicine

The objective of the Centre for Molecular Medicine is to identify, study and understand the functions of molecules and biological processes involved in the development of diseases. Currently the Centre is focused on the causes of Crohn’s disease, which it has shown result from immunodeficiency, and ulcerative colitis. Find out more at http://www.ucl.ac.uk/molecular-medicine

About the UCL Institute of Neurology

The Institute of Neurology was established in 1950, merged with UCL in 1997, and is a key component of the Faculty of Brain Sciences at UCL. Together with the National Hospital for Neurology and Neurosurgery, an adjacent facility with which it cooperates closely, the Institute forms a major centre for teaching, training and research in neurology and allied clinical and basic neurosciences. Find out more at http://www.ucl.ac.uk/ion/about

About Macrogen

Macrogen, Inc. (www.macrogen.com), based in Seoul, Korea, is a world leading service provider in high-quality gene analysis and has enjoyed stable and steady growth since 1997. Macrogen Inc. has been dedicated to provide a reliable and efficient service of DNA Sequencing and bioinformatics with profound knowledge and unbeatable amount experience over 17 years. The company’s diverse offerings include DNA sequencing, next generation sequencing, microarray analysis, oligonucleotide synthesis, DNA chip and genetically engineered mice services. We serve over +17,000 customers from academic research and industry in 120 countries around the globe and have subsidiary companies in USA, Japan and Europe, headquartered in South Korea. Find out more at http://www.macrogen.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20150518005345/en/

CONTACT

Macrogen Inc.
Yonghwan Kang, +82-2-2113-7113
snatch@macrogen.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作
  • ベルタンとザイモリサーチが新しい連携を発表
  • The First China (Chongqing) Selenium Enrichment Industry Development Conference, Organized by the Chongqing Jiangjin Agriculture Commission, Was Held in Jiangjin